GlassScriptPhysician profile
Mary Udseth
NPI 1922400720
$9,472.49
in general payments reported to CMS, 2019-2025
44 companies · $1,717 in 2025
The $1,717 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,300 · 2022: $1,938 · 2023: $1,930 · 2024: $1,588 · 2025: $1,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,235.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,466.38 | 2021-2025 | |
| Novo Nordisk INC | $1,155.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $827.60 | 2021-2025 | |
| Lilly USA, LLC | $760.28 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $716.50 | 2021-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $502.43 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.19 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $387.91 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $317.34 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $297.14 | 2021-2025 | Gardasil 9, Capvaxive, Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.49 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $263.89 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $253.67 | 2022 | |
| Esperion Therapeutics, INC. | $223.60 | 2021-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $172.03 | 2021-2024 | Trintellix |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $152.79 | 2021-2024 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $133.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $120.05 | 2021-2024 | |
| Lundbeck LLC | $108.69 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $94.96 | 2021-2025 | |
| Eisai INC. | $70.46 | 2021-2022 | |
| Dexcom, INC. | $66.99 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $58.95 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $54.87 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $51.95 | 2023-2025 | Eliquis, Camzyos |
| Axsome Therapeutics, INC. | $44.95 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $42.83 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $39.30 | 2021-2022 | |
| Halozyme INC | $33.63 | 2023 | |
| Nevro Corp. | $31.97 | 2022-2023 | Senza |
| Acerus Pharmaceuticals Corporation | $28.31 | 2021-2022 | |
| Seqirus USA INC | $28.03 | 2021 | |
| Corcept Therapeutics | $26.62 | 2023 | Korlym |
| Bausch Health US, LLC | $23.95 | 2022 | |
| Neurelis, INC. | $23.53 | 2023 | Valtoco |
| Cumberland Pharmaceuticals, INC. | $21.32 | 2024 | Kristalose |
| Watermark Medical, INC. | $19.77 | 2024 | |
| Medtronic, INC. | $19.55 | 2022 | |
| Tactile Systems Technology INC | $19.10 | 2023 | Flexitouch Plus, Entre Plus |
| Xeris Pharmaceuticals, INC. | $17.82 | 2025 | Gvoke Hypopen |
| Antares Pharma, INC. | $17.45 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.21 | 2023 | Xyosted, Qelbree, Tlando |
| Kowa Pharmaceuticals America, INC. | $14.06 | 2023 | Livalo, Seglentis |
| Aytu Biopharma, INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Udseth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.